A, study design for measuring the feasibility, concordance, and accuracy of a plasma-based cfDNA sequencing test compared with biopsy-based sequencing.

Slides:

Advertisements

Similar presentations

Genome evolution within the individual

Advertisements

Anna Buder Institute of Cancer Research Department of Medicine I Medical University of Vienna Liquid Biopsies Analysis of circulating cell-free tumor-DNA.

Fig. 1 Selection of patients

Summary of genetic alterations in resistant biopsies among patients progressing on ceritinib or alectinib. Summary of genetic alterations in resistant.

Adrian G. Sacher, MD, Kimberly M. Komatsubara, MD, Geoffrey R

Ewing sarcoma tumors acquire somatic aberrancies with treatment.

Regional lymph nodes and distal extracranial metastases are not a reliable surrogate for actionable mutation in brain metastases. Regional lymph nodes.

T790M Mutation-Positive NSCLC: A Multidisciplinary Case Conference

Somatic mutations in mitochondrial DNA do not associate with nuclear microsatellite instability in gastrointestinal cancer Simó Schwartz, M.D., Ph.D.*,†,

Clonal evolution in Ewing sarcoma.

Quantitative Measurement of Cell-Free Plasma DNA and Applications for Detecting Tumor Genetic Variation and Promoter Methylation in a Clinical Setting

Intrinsic and acquired trastuzumab resistance.

High-throughput analysis of informative CpG sites for the four studied tumor suppressor genes (A-D). High-throughput analysis of informative CpG sites.

Identification of a MEK2 mutation in a melanoma sample resistant to dabrafenib/trametinib. Identification of a MEK2 mutation in a melanoma sample resistant.

Detection rate for EGFR mutations in cfDNA.

Whole-exome sequencing identifies NF1 mutations in tumors of melanoma patients exhibiting resistance to vemurafenib. Whole-exome sequencing identifies.

A Rapid, Sensitive Assay to Detect EGFR Mutation in Small Biopsy Specimens from Lung Cancer Yasushi Yatabe, Toyoaki Hida, Yoshitsugu Horio, Takayuki.

Detection rate of EGFR mutations in cfDNA by characteristics

Integrative statistical analysis pipeline for RNA-seq and NanoString with application to gene expression data of cancer patients Jeea Choi, Catarina D.

Presentation and progression of glioblastoma with PNET features in an adult patient. Presentation and progression of glioblastoma with PNET features in.

Treatment and diagnosis history, and response to targeted therapy, of a patient with pancreatic adenocarcinoma with an EGFR exon19 deletion. Treatment.

High-level clonal amplification of FGFR2 predicts for sensitivity to FGFR inhibitor. High-level clonal amplification of FGFR2 predicts for sensitivity.

Fig. 1. Schematic showing the shedding of tumor DNA from head and neck cancers into the saliva or plasma. Schematic showing the shedding of tumor DNA from.

Fig. 2 Estimate of the neoantigen repertoire in human cancer.

Genetic Features of Chinese Patients with Gitelman Syndrome:

Fig. 1. Detection of circulating tumor DNA in CRPC patients.

On the left, Euler-Venn diagram of point mutations detected by lbNGS and ttNGS on matched genes from the same patients; on the right, the percentage of.

BRCA1 promoter methylation detected in the peripheral blood and corresponding tumor. BRCA1 promoter methylation detected in the peripheral blood and corresponding.

FAK overexpression in invasive human breast cancer and DCIS

Temporal analysis of clonal evolution in typical FL and matched TFL samples. Temporal analysis of clonal evolution in typical FL and matched TFL samples.

Integrated mRNA and microRNA expression and DNA methylation clusters.

Frequent alterations identified and potential actionability.

IL6 mRNA is not detected in metastatic prostate cancer cells.

A, scatterplots of qMSP analysis of candidate genes promoters in the prevalence screen cohort, which consisted of 55 HNSCC tumor tissue samples and 37.

KIT mutations in GISTs. A, amino acid sequence of KIT exon 11 mutations in clinical GIST biopsies. –, amino acids that are deleted; italicized amino acids,

Predictive value of the FGFR3 mutation assay increases with multiple consecutive FGFR3-positive urine samples. Predictive value of the FGFR3 mutation assay.

Saturation analysis and the discovery of actionability of mutational hotspots. Saturation analysis and the discovery of actionability of mutational hotspots.

The truncating mutation c

A, Proportion of variants detected in the MMR genes.

Plasma and tissue EGFR allele analyses.

Delineation of the clinical course and evolution of BRAF mutation status in the seven patients with BRAF V600E mutation. Delineation of the clinical course.

Targetable alterations and pathways in TNBCs after NAC

Comparison of the frequency of nucleotide variation in the mtDNA D-loop region between stomach and other tumor cell lines. Comparison of the frequency.

Kaplan-Meier survival analysis of p53 mutation in the overall breast tumor series. Kaplan-Meier survival analysis of p53 mutation in the overall breast.

Nested RT-PCR of Mammaglobin and CK19 mRNA in plasma and circulating cells of controls (C) and patients (T) with breast cancer. Nested RT-PCR of Mammaglobin.

Number of identical D-loop DNA clones detected in 10 DNA clones derived from liver tumor tissues. Number of identical D-loop DNA clones detected in 10.

Representative photograph of somatic mutations detected by PCR-SSCP.

Reduced klotho expression in pancreatic cancer.

Clustering analysis of DTC-associated genes.

Intratumoral changes in critical lymphocyte populations and numbers after NKTR-214 treatment. Intratumoral changes in critical lymphocyte populations and.

Fig. 1 Number of somatic mutations in representative human cancers, detected by genome-wide sequencing studies. Number of somatic mutations in representative.

Cropped 2D gel images of selected proteins in normal, pancreatitis, and tumor tissues. Cropped 2D gel images of selected proteins in normal, pancreatitis,

Identification of general and tissue-specific essential genes.

Frequently mutated genes in colorectal cancer.

Molecular definitions of lung adenocarcinoma subtypes.

Concordance between the genomic landscape identified by whole-exome sequencing of plasma cfDNA and tumor; DNA and recurrence of KDR/VEGFR2 oncogenic mutations.

Landscape of genomic alterations identified by WES in biopsies of patients with advanced PDAC. Co-mutation plot displaying integrated genomic data for.

Enrichment of two rare SNPs among ABC DLBCL tumors.

Concordance between liquid versus tissue biopsies.

One potential implementation for the use of outlier kinase profiling and targeting for clinical management of pancreatic cancer in a precision medicine.

A, Changes in BRAFV600E cfDNA allele fraction from baseline after one dose of treatment for 12 patients with serial samples available, classified according.

Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy. Detection of BRCA reversion mutations in pretreatment cfDNA and tumor biopsy.

Core melanoma escape pathways during disease progression on BRAF inhibitor therapy. Core melanoma escape pathways during disease progression on BRAF inhibitor.

A–D, FGFR3 gatekeeper mutations detected in 4 patients.

High genomic fidelity of SCLC PDX models derived from both CTCs and biopsies. High genomic fidelity of SCLC PDX models derived from both CTCs and biopsies.

CD36 expression in tissue adjacent and distal to the tumor.

Driver pathways and key genes in OSCC

BIM expression predicts the response of patients with EGFR-mutant lung cancers. BIM expression predicts the response of patients with EGFR-mutant lung.

Molecular characterization of esophagogastric tumors.

Presentation transcript:

A, study design for measuring the feasibility, concordance, and accuracy of a plasma-based cfDNA sequencing test compared with biopsy-based sequencing tests for patients with pancreatic and biliary cancers [in accordance with Standards for the Reporting of ... A, study design for measuring the feasibility, concordance, and accuracy of a plasma-based cfDNA sequencing test compared with biopsy-based sequencing tests for patients with pancreatic and biliary cancers [in accordance with Standards for the Reporting of Diagnostic accuracy studies (STARD)]. Sixteen patients had mutations detected by either type of test, and 1 patient had no mutations detected in either plasma or in tumor tissue (n = 17). B, Oncoprint chart showing mutation occurrence for the top seven genes across all patients. The group at left (“Concordance”) shows mutations detected in the 17 samples used for the concordance analysis (see Fig. 2B). The group at right (“QNS”) shows mutations detected in cfDNA from the eight QNS samples. TND, tumor DNA not detected in cfDNA. Oliver A. Zill et al. Cancer Discovery 2015;5:1040-1048 ©2015 by American Association for Cancer Research